Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
J Control Release. 2012 May 30;160(1):96-104. doi: 10.1016/j.jconrel.2012.01.032. Epub 2012 Jan 27.
A challenge in ocular drug delivery is to maintain the therapeutic concentration of a drug at the site of action in the eye. The objective of the present study was to investigate the feasibility of micellar carrier systems for sustained drug delivery in transscleral iontophoresis in vitro. Simple and mixed micelles prepared using sodium taurocholate (TA) alone or with egg lecithin (LE) were the carrier systems studied. Dexamethasone (DEX), a poorly water soluble corticosteroid, was the model drug. The micellar carrier systems were first characterized for their solubilization and encapsulation of the drug. Passive and 2-mA iontophoretic (both cathodal and anodal) transport experiments were conducted using these micellar carrier systems in side-by-side diffusion cells with excised human sclera in vitro. Drug release studies were performed after the transport experiments. Saturated DEX solution without the micellar carriers was used as a control. It was found that the solubilization capacity of the micellar carrier systems increased as the total lipid concentration of the systems increased. Drug release from the sclera was significantly prolonged with the micellar carrier systems as compared to the control after passive and iontophoretic delivery. Less than ~20% of DEX was released from the sclera in approximately 2h after cathodal iontophoretic delivery of the micellar carrier systems, whereas more than ~50% of DEX was released from the control in the same time period under the same condition. Micellar carrier systems can be a suitable transscleral drug delivery system for poorly water soluble drugs by enhancing their aqueous solubilities and providing sustained drug delivery. These micellar carrier systems can be efficiently delivered into and across the sclera by iontophoresis for drug delivery.
眼用药物输送的一个挑战是维持药物在眼部作用部位的治疗浓度。本研究的目的是研究胶束载体系统在体外经皮离子导入递药中的可行性。研究的载体系统是单独使用牛磺胆酸钠(TA)或与卵磷酯(LE)制备的简单胶束和混合胶束。地塞米松(DEX)是一种水溶性差的皮质类固醇,作为模型药物。首先对胶束载体系统的药物增溶和包封能力进行了表征。在体外双侧扩散池用人硬脑膜进行了被动和 2 mA 离子电渗(阴极和阳极)传输实验。在传输实验后进行药物释放研究。将不含胶束载体的饱和 DEX 溶液作为对照。结果发现,随着系统总脂质浓度的增加,胶束载体系统的增溶能力增加。与对照相比,经皮离子导入后,胶束载体系统的药物释放明显延长。在阴极离子电渗给药后约 2 小时内,胶束载体系统从硬脑膜中释放的 DEX 不到约 20%,而在相同条件下,对照在同一时间内释放的 DEX 超过约 50%。胶束载体系统可以通过提高其水溶解度和提供持续药物输送,成为一种用于治疗水溶性差的药物的合适的经皮药物输送系统。这些胶束载体系统可以通过离子电渗有效地输送到硬脑膜中并穿过硬脑膜进行药物输送。